- Home
- KPRX vs GREE Comparison
KPRX vs GREE Comparison
Compare KPRX & GREE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- GREE
- Stock Information
- Founded
- KPRX 1998
- GREE 1937
- Country
- KPRX United States
- GREE United States
- Employees
- KPRX N/A
- GREE N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- GREE Investment Bankers/Brokers/Service
- Sector
- KPRX Health Care
- GREE Finance
- Exchange
- KPRX Nasdaq
- GREE Nasdaq
- Market Cap
- KPRX 8.3M
- GREE 9.8M
- IPO Year
- KPRX N/A
- GREE N/A
- Fundamental
- Price
- KPRX $3.18
- GREE $0.83
- Analyst Decision
- KPRX Strong Buy
- GREE Strong Buy
- Analyst Count
- KPRX 1
- GREE 1
- Target Price
- KPRX $10.00
- GREE $4.00
- AVG Volume (30 Days)
- KPRX 10.5K
- GREE 149.7K
- Earning Date
- KPRX 05-09-2025
- GREE 05-14-2025
- Dividend Yield
- KPRX N/A
- GREE N/A
- EPS Growth
- KPRX N/A
- GREE N/A
- EPS
- KPRX 0.87
- GREE N/A
- Revenue
- KPRX $16,020,000.00
- GREE $59,533,000.00
- Revenue This Year
- KPRX N/A
- GREE N/A
- Revenue Next Year
- KPRX N/A
- GREE N/A
- P/E Ratio
- KPRX $3.56
- GREE N/A
- Revenue Growth
- KPRX N/A
- GREE N/A
- 52 Week Low
- KPRX $2.51
- GREE $0.58
- 52 Week High
- KPRX $5.76
- GREE $3.84
- Technical
- Relative Strength Index (RSI)
- KPRX 55.96
- GREE 57.35
- Support Level
- KPRX $2.64
- GREE $0.61
- Resistance Level
- KPRX $3.25
- GREE $0.87
- Average True Range (ATR)
- KPRX 0.19
- GREE 0.07
- MACD
- KPRX 0.06
- GREE 0.03
- Stochastic Oscillator
- KPRX 74.32
- GREE 85.52
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About GREE Greenidge Generation Holdings Inc.
Greenidge Generation Holdings Inc owns and operates a vertically integrated cryptocurrency data center and power generation company. The company owns and operates facilities at two locations: the Town of Torrey, New York, and Spartanburg, South Carolina. The cryptocurrency data center operations generate revenue in the form of bitcoin by earning bitcoin as rewards and transaction fees for supporting the bitcoin network with application-specific integrated circuit computers (ASICs or miners) owned or leased by the company.